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Purpose. To assess diﬀerences in dose distribution of a vertebral body injected with bone cement as calculated by radiation
treatment planning system (RTPS) and actual dose distribution. Methods. We prepared two water-equivalent phantoms with
cement, and the other two phantoms without cement. The bulk density of the bone cement was imported into RTPS to reduce
error from high CT values. A dose distribution map for the phantoms with and without cement was calculated using RTPS with
clinicalsettingandwiththebulkdensityimporting.Actualdosedistributionwasmeasuredbytheﬁlmdensity.Dosedistributionas
calculated by RTPS was compared to the dose distribution measured by the ﬁlm dosimetry. Results. For the phantom with cement,
dose distribution was distorted for the areas corresponding to inside the cement and on the ventral side of the cement. However,
dose distribution based on ﬁlm dosimetry was undistorted behind the cement and dose increases were seen inside cement and
around the cement. With the equivalent phantom with bone cement, diﬀerences were seen between dose distribution calculated
by RTPS and that measured by the ﬁlm dosimetry. Conclusion. The dose distribution of an area containing bone cement calculated
using RTPS diﬀers from actual dose distribution.
1.Introduction
Pain due to bone metastasis is one of the prevalent compli-
cations of cancer [1–5]. Though the value of vertebroplas-
ty for osteoporotic fracture is discussed [6, 7], even now
Percutaneous vertebroplasty has been considered one of
good therapeutic options for alleviating pain caused by
malignant vertebral tumors, such as multiple myeloma
and metastatic vertebral tumor [8–15]. Radiotherapy is
gold standard treatment for pain associated with metastatic
bone tumor. The National Comprehensive Cancer Network
guidelines [16] and Ontario guidelines [17] recommend
radiotherapy for alleviating the pain associated with bone
metastasis.
In the treatment of metastatic spinal bone tumor, com-
bination therapy consisting of vertebroplasty and radiother-
apy has been performed [18, 19]. In future, radiotherapy
combinedwithpercutaneousvertebroplastyisexpectedtobe
performed more frequently.
Bone cement used in percutaneous vertebroplasty con-
tains about 30% barium, a radio-opaque agent [10–13]. The
X-rayabsorption valueofcementcontaining about30% bar-
ium is very high (computed tomography (CT) value: 1600–
3000 HU). When planning three-dimensional radiotherapy
using CT images following percutaneous vertebroplasty,
bone cement containing barium in vertebral bodies may
aﬀect the dose distribution of radiotherapy, but no basic
data are available regarding the eﬀects of bone cement on2 Radiology Research and Practice
Figure 1: The middle phantom is a number 23 RANDO phantom.
The upper and lower phantoms are water-equivalent phantoms
modeled after the anthropomorphic phantom, and a test hole
corresponding to the second lumbar vertebral body has been
hollowed out. Testing sample such as PMMA and Toughwater
Phantom is set in the hole.
dose distribution. The objective of the present study was
to clarify the eﬀects of bone cement containing barium in
vertebral bodies on dose distribution and the diﬀerences
in dose distribution calculated using a radiation treatment
planning system (RTPS) and actual dose distribution.
2.MaterialsandMethods
2.1. Phantom Preparation. Four water-equivalent phantoms
(Toughwater Phantom, 1-cm thickness, 1.018g/cm3,K y o t o
Kagaku CO., Kyoto, Japan) were prepared by tracing the
shapeoftheanthropomorphicphantom(RANDOphantom,
Kyoto Kagaku CO., Kyoto, Japan) at the second lumbar
vertebra (between number 23 and 24) according to ICRU
Report number 44.
With two water-equivalent phantoms, the area corre-
sponding to the second lumbar vertebral body was scooped
out as shown in Figure 1. Twenty grams of methylmethacryl-
ate powder (Osteobond copolymer bone cement; Zimmer,
Warsaw, IN, USA) was mixed with 5 grams of barium
sulfate powder (Horii Pharmaceutical, Osaka, Japan). Ten
milliliters of liquid methylmethacrylate monomer was added
to the resulting powder, and the mixture was blended to a
toothpaste-likeconsistencytoproducepolymethylmethacry-
late (PMMA). The resulting polymethylmethacrylate was
then poured into the hollowed-out area of the water-
equivalent phantoms and then cured to prepare water-
equivalent phantoms with bone cement. With the remaining
two water-equivalent phantoms, bone cement was not
poured (control).
2.2. Calculation of Dose Distribution. The water-equivalent
phantom modeled after the second lumbar vertebra was
Figure 2: A ﬁlm (EDR2) is located between two water-equivalent
phantoms.Theywereﬁrmlysetintheanthropomorphicphantoms,
and radiation was irradiated.
subjected to CT (Asteion 4; Toshiba Medical Systems, Tokyo,
Japan) (imaging condition: 120kV; 250mA; 5mm slice
thickness). CT image data was transferred to a radiation
treatment planning system (Eclipse Treatment Planning
System, version 8.1; Varian Medical Systems, CA, USA) to
plan radiotherapy. An isocenter for radiotherapy was set
inside the spinal cord on a target slice, and a 10cm ×
10cm irradiation ﬁeld was established around the isocenter
for posterior single ﬁeld irradiation. The reference point
for radiotherapy was set at the isocenter. Using 4-MV X-
ray, 1Gy of radiation was irradiated. Using the treatment
planningsystemwithclinicalsetting,adosedistributionmap
was prepared for the water-equivalent phantoms with and
without bone cement.
Additionally, we imported thebulkdensity (1.303g/cm3)
of the bone cement into the treatment planning system to
reduce error from high CT values, and a dose distribution
map was again prepared for the water-equivalent phantoms
with and without bone cement.
2.3. Measurement of Dose Distribution by the Film Dosimetry.
A ﬁlm (EDR2; Eastman Kodak Co., Rochester, NY, USA) was
placed between two water-equivalent phantoms (Figure 2).
Under the same conditions for measuring dose distribution
using RTPS, linear accelerator (clinac21EX; Varian Medical
Systems, CA, USA) was used to irradiate 1Gy of 4-MV X-
ray. As a reference point, 100% dose was irradiated. Films
were developed and read using a universal ﬂat-bed scanner
(ES-10000G; Epson, Nagano, Japan), and a dose distribution
analysis system (DD-System, DD-Analysis version 8.0, DD-
IMRT version 8.0 and DD-Scan version 3.0; R-Tech, Tokyo,
Japan) was used to measure dose distribution based on the
ﬁlm density [20]. Dose distribution was assessed by deﬁning
the isocenter on each ﬁlm as the origin (coordinate: 0),Radiology Research and Practice 3
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Figure 3: The calculated dose distribution maps using RTPS and the dose distribution maps measured by ﬁlm dosimetry. (a) with the
phantom without bone cement, the calculated dose distribution was undistorted. (b) with the phantom with bone cement, using RTPS with
clinical setting, a depression in the isodose curve was seen for areas corresponding to inside the cement and the ventral side of the cement.
(c) with the phantom with bone cement, using RTPS with importing the bulk density of the bone cement, dose inside the cement was the
same as in the surrounding area. A depression in the isodose curve was seen in the ventral side of the cement however, the distortion with
importing the bulk density of the bone cement (c) was less than with clinical setting (b). (d) with the phantom without bone cement, no
distortion and no diﬀerence in the isodose curve were seen between calculated dose distribution (a) and measured dose distribution (d).
(e) with the phantom with bone cement, a dose distribution map drawn by the ﬁlm-based dose distribution analysis system. Dose increases
were seen within and around bone cement. No signiﬁcant dose decrease was seen behind bone cement.
left-right direction as the X-axis and anteroposterior direc-
tion as the Y-axis.
Eﬀects of bone cement on irradiation as assessed by
the ﬁlm dosimetry were investigated by comparing dose
distribution between water-equivalent phantoms with and
without bone cement. Dose distribution as calculated by
RTPS was compared to the dose distribution measured by
the ﬁlm dosimetry.
3. Results
3.1. Dose Distribution Calculated by RTPS. For the water-
equivalent phantom without bone cement, dose distribution
calculated using RTPS both with clinical setting and with
importing the bulk density of the bone cement was even and
undistorted (Figure 3(a)).
For the water-equivalent phantom with bone cement,
dose distribution calculated with clinical setting was dis-
torted for the areas corresponding to inside the cement and
on the ventral side of the cement. In other words, dose inside
the cement was lower than in the surrounding area. Dose for
the ventral side (the side through which radiation had passed
through the cement) was lower than that for the dorsal side
(the side through which radiation had yet to pass through
the cement). A dose distribution map showed that dose was
lower for the area after the cement (Figure 3(b)).
For the water-equivalent phantom with bone cement,
dose distribution calculated with importing the bulk density
of the bone cement was not distorted for the areas corre-
sponding to inside the cement but distorted on the ventral
side of the cement. Dose inside the cement was the same as
in the surrounding area. Dose for the ventral side was lower4 Radiology Research and Practice
than that for the dorsal side; however, the distortion with
importing the bulk density of the bone cement was less than
with clinical setting (Figure 3(c)).
3.2. Analysis by the Film-Based Dose Distribution Analysis
System. For the equivalent phantom without bone cement,
dose distribution was undistorted (Figure 3(d)). For the
equivalent phantom with bone cement, dose increases were
seen inside cement and around the cement (Figure 3(e)).
In the Y-axis direction, between the equivalent phantom
with bone cement and the equivalent phantom without bone
cement, diﬀerences existed inside and outside the cement.
Dose increase inside bone cement was 8.94 cGy ± 2.78
(maximum, 15.64 cGy). Outside bone cement, dose increase
was found only before bone cement, but no dose increase
was seen after cement. Area with dose increase outside
bone cement was 2.33mm ± 1.03 (maximum, 3.0mm).
Dose increase outside bone cement was 1.35 cGy ± 0.68
(maximum, 2.68 cGy).
Dose distribution was analyzed in the X-axis direction
at the maximum width of bone cement. Dose increases were
seen inside and outside bone cement. Dose increase inside
bone cement was 12.19 cGy ± 2.27 (maximum, 16.73 cGy).
Area with dose increase outside bone cement was 11.50mm
± 2.66 (maximum, 15.0mm). Dose increase outside bone
cement was 3.65 cGy ± 1.54 (maximum, 8.35 cGy).
3.3. Comparison of Dose Distribution as Calculated by Treat-
ment Planning and Film-Based Dose Distribution Analysis.
With the equivalent phantom without bone cement, no
diﬀerence and no distortion were seen between dose distri-
bution calculated by RTPS and that measured using the ﬁlm-
based dose distribution analysis system.
With the equivalent phantom with bone cement, dif-
ferences were seen between dose distribution calculated by
RTPS and that measured by the ﬁlm-based dose distribution
analysis system. Dose at the bone cement as calculated
by RTPS with clinical setting was lower than that in the
surrounding area, and with importing the bulk density of
the bone cement was similar to that in the surrounding
area, but dose at the bone cement as calculated by the ﬁlm
dosimetry was higher than that in the surrounding area.
Dose for the area after bone cement was lower than that for
adjacent area according to RTPS with clinical setting, but
the dose distribution calculated by RTPS with importing the
bulk density of the bone cement and the dose distribution
measured using the dose distribution analysis system did not
conﬁrm any dose reduction after bone cement.
4. Discussion
Three-dimensional radiotherapy planning is based on CT,
but when performing radiotherapy following percutaneous
vertebroplasty, bone cement containing barium in vertebral
bodies can aﬀect the dose distribution of radiotherapy. The
present basic study using water-equivalent phantoms was
performed to clarify the eﬀects of bone cement containing
barium in vertebral bodies by percutaneous vertebroplasty
on dose distribution during radiotherapy and to ascertain
diﬀerencesbetweendosedistributioncalculatedbyRTPSand
actual dose distribution.
The RTPS cannot handle the conversion from these
high CT values to electron densities, and the barium could
have generated CT artifacts making the contouring of the
area with bone cement less accurate. Therefore, the authors
imported the bulk density of the bone cement into the
RTPS. By assuming that the bulk density of the cement is
also the electron density relative to water, probably a much
more realistic dose distribution will be obtained. This is in
fact the procedure recommended for other situations where
high-Z materials, such as hip prostheses, cause CT artefacts,
as outlined in Report of the AAPM Radiation Therapy
Committee Task Group 63 [21].
4.1. Dose Increase Inside and Around Bone Cement. In our
study, dose increases were seen within and before and to the
lateral sides of bone cement. Dose increase could have been
caused by scattering of radiation by the cement. However,
no signiﬁcant dose increase was conﬁrmed after cement.
In particular, dose increase before cement could have been
caused by backscattering of irradiation by the cement. The
distance from vertebral bodies to spinal cord is about 2mm.
In the present study, the area with dose increase outside bone
cementcausedbybackscatteringofirradiationwas2.33mm,
and the degree of dose increase outside bone cement was
1.35 cGy. Therefore, spinal cord dose can appear to exceed
planned dose.
4.2. Dose Distribution. In treatment planning using RTPS,
the dose decrease was calculated after passing through bone
cement. However, no signiﬁcant dose decrease was seen by
the ﬁlm dosimetry.
In radiotherapy for metastatic bone tumors in the tho-
racic and lumbar vertebrae, posterior single-ﬁeld irradiation
is generally performed. When performing posterior single
ﬁeld irradiation for thoracolumbar vertebrae, caution must
be exercised on spinal cord dose. As reported by Emami
et al. [22], the dose resulting in a 5% probability of this
devastating complication such as radiation myelitis within
5 years of treatment (TD 5/5) has been estimated at 50Gy,
and 45Gy has commonly been used as a maximum dose in
clinicalpractice.Thecaudaequina,consistingofspinalnerve
roots, has been found to have a slightly higher tolerance,
with an estimated TD 50/5 of 60Gy [22]. In the present
study, there was back scattering, but spinal cord dose can not
appear to extremely exceed planned dose. Hence, even with
vertebral bodies with bone cement placed by percutaneous
vertebroplasty, when performing radiotherapy by posterior
single ﬁeld irradiation, spinal cord dose is a little aﬀected.
In recent years, new radiotherapeutic techniques such
as intensity-modulated radiation therapy (IMRT) and body
stereotactic radiotherapy have been performed [23–26].
When performing radiotherapy for paravertebral tumors
aroundvertebralbodies(e.g.,lungcancer,esophagealcancer,
and pancreatic cancer) following bone cement injection, if
bonecementexistswithinanirradiationﬁeld,thenRTPSwill
calculate radiation dose after the bone cement as low, but inRadiology Research and Practice 5
reality, since bone cement does not aﬀect radiation dose, a
higher dose of radiation may be delivered over a broader area
than expected.
The diﬀerence between the dose distribution calculated
using RTPS and the dose distribution measured by the ﬁlm
dosimetry could be explained as follows. First, bone cement
has as high as 30% barium concentration. The RTPS did
not have data for the eﬀects of an artiﬁcial material (bone
cement containing barium) on dose distribution. Secondly,
bone cement containing barium could have generated CT
artifacts. Hence, if bone cement exists within an irradiation
ﬁeld during treatment planning, expected dose distributions
may diﬀer from actual dose distribution. Importing the bulk
density of the bone cement into RTPS could decrease the
diﬀerence between the dose distribution calculated using
RTPS and the dose distribution measured by the ﬁlm
dosimetry.
Inconclusion,thedosedistributionofanareacontaining
bone cement calculated using RTPS diﬀers from actual dose
distribution.
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